CagriSema: difference between revisions
Diff·revision 9 → 10·04:29, 8 Feb 2025
Difference between revision 9 and revision 10 of CagriSema. 6 lines changed; the page grew by 787 bytes.
| Revision 9 — 06:11, 27 Jan 2025 UnderfillUna (talk) add the molecular formula to the infobox 2,989 bytes +74 | Revision 10 — 04:29, 8 Feb 2025 Hedgerow_Hal (talk) add the excipient list from the labelling 3,776 bytes +787 | ||
|---|---|---|---|
| 1 | {{Infobox compound | 1 | {{Infobox compound |
| 2 | | name = CagriSema | 2 | | name = CagriSema |
| + | 3 | | subtitle = Investigational combination | |
| 3 | | Components = [[Cagrilintide]] and [[Semaglutide]] | 4 | | Components = [[Cagrilintide]] and [[Semaglutide]] |
| 4 | | Form = Fixed-ratio co-formulation, single injection | 5 | | Form = Fixed-ratio co-formulation, single injection |
| ⋮ | ⋮ | ||
| 20 | 21 | ||
| 21 | The co-formulation approach was chosen over a unimolecular design because no scaffold engages both the [[GLP-1 receptor]] and an amylin receptor — the receptor families are not related in the way the incretin and glucagon receptors are, so the trick that produced [[Tirzepatide|tirzepatide]] is not available here.{{r|frias2023cagri}} | 22 | The co-formulation approach was chosen over a unimolecular design because no scaffold engages both the [[GLP-1 receptor]] and an amylin receptor — the receptor families are not related in the way the incretin and glucagon receptors are, so the trick that produced [[Tirzepatide|tirzepatide]] is not available here.{{r|frias2023cagri}} |
| + | 23 | ||
| + | 24 | == Reported findings == | |
| + | 25 | A phase 2 trial in type 2 diabetes reported greater glycated-haemoglobin and weight reduction with the combination than with either component alone at 32 weeks. The phase 3 obesity programme has reported mean weight reduction in the region of 20% at 68 weeks, with the caveat that a substantial proportion of participants did not reach the highest planned doses.{{r|frias2023cagri}} | |
| + | 26 | ||
| + | 27 | That last point has attracted attention: an efficacy figure obtained when many participants remained on lower doses is not the same as an efficacy figure at the target dose, and the two interpretations of the result — that the ceiling was not reached, or that dose escalation is the practical limit — have different implications. | |
| 22 | 28 | ||
| 23 | == References == | 29 | == References == |